Guizhou Bailing Group Pharmaceutical Co., Ltd.'s (SZSE:002424) Prospects Need A Boost To Lift Shares

Simply Wall St19:14 ET

GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong FinanceMar 16 21:18 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

ST Bering: 2024 Annual Results Forecast

SZSIJan 24 11:00 ET · Announcements

Painful Week for Retail Investors Invested in Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) After 7.0% Drop, Institutions Also Suffered Losses

Simply Wall StDec 24, 2024 00:14 ET

Special treat Burin (002424.SZ): The small-scale testing of the new process route for the Tefentai project has successfully concluded and is currently undergoing pilot verification.

Gelonghui, December 3rd, ST BaiLing (002424.SZ) stated on the investor interaction platform that the trial of the new process route for the Teofinde project has successfully concluded, and is currently undergoing pilot verification. If successful, samples can be produced according to the new process to conduct clinical trials for drug interactions.

Gelonghui FinanceDec 3, 2024 03:17 ET